Moreover, I was pleasantly surprised that neither it's up to $2 billion deal with United Biotechnology to develop UBT251 [GLP-1/GIP/GCG triagonist] for the treatment of cardiometabolic diseases ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...